New contract marks the 20th state in the nation where Syra has active contractsCARMEL, Ind., May 28, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today that it has been awarded a contract by the Health Care Authority (HCA) in Washington State to provide essential behavioral health and recovery training and support services. This ...

CARMEL, Ind., May 20, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today that it has been awarded a one-year contract with annual extensions for up to five years to provide Special Education (SPED) Psychologist Services for the Greenville County School District in South Carolina.Per the contract, Syra Health will provide ongoing ...

财务数据和关键指标变化 - 第一季度收入为1.7亿美元,同比增长47% [20] - 数字健康业务收入为92,000美元,主要来自SyraBot产品销售 [13] - 人口健康业务收入为232,000美元,同比增长213% [21] - 医疗工作力量业务收入增长28%,达到1.4亿美元 [21] - 行为与心理健康以及健康教育业务合计收入为11,000美元 [21] - 毛利率为10.2%,同比下降2.2个百分点 [22] - 净亏损为1.4亿美元,同比增加0.6亿美元 [24] - 调整后EBITDA为负1.4亿美元,同比下降0.6亿美元 [24] 各条业务线数据和关键指标变化 - 数字健康业务收入增长,主要来自SyraBot产品销售 [13] - 人口健康业务收入大幅增长,主要得益于疫情防控服务需求 [10][11] - 医疗工作力量业务收入增长,得益于新客户和合同扩展 [12] - 行为与心理健康以及健康教育业务收入较小,但增长迅速 [14][15][17] 各个市场数据和关键指标变化 - 公司目前在19个州开展业务,是公司成立3年来的重大成就 [6] - 公司正在积极拓展联邦政府市场,已获得联邦政府合同 [7][18] 公司战略和发展方向以及行业竞争 - 公司专注于心理健康、数字健康和人口健康等领域,提供创新解决方案 [5][9] - 公司正在开发Syrenity、SyraBot和Care Plus等新技术产品,有望成为公司未来增长动力 [9] - 公司正在扩大销售团队和业务开发,复制现有项目以获得更多客户 [27] - 公司看好心理健康等领域的发展前景,认为这些领域存在巨大需求 [14] 管理层对经营环境和未来前景的评论 - 公司2024年收入指引为9-11亿美元,同比增长64%-100% [25] - 公司认为自身在技术创新和专业人才方面的优势,有助于获得更多合同 [32][33] - 公司看好人口健康业务的发展前景,认为这一领域存在强劲需求 [35] - 公司预计2024年下半年收入将更多体现,因为客户实施周期较长 [30] 问答环节重要的提问和回答 问题1 **提问内容** 2024年收入指引的时间分布情况 [29] **回答内容** 公司预计2024年收入主要集中在下半年,因为客户实施周期较长 [30] 问题2 **提问内容** 公司成功获得众多合同的原因 [31] **回答内容** 公司拥有经验丰富的专业团队,提供创新的服务和技术解决方案,这是公司成功的关键 [32][33] 问题3 **提问内容** 人口健康业务增长强劲的原因 [34] **回答内容** 公司擅长开展差距分析,了解客户需求,凭借专业的流行病学和研究团队,在这一领域获得强劲需求 [35]

Exhibit 99.1 Syra Health Announces First Quarter 2024 Financial Results, Led By Strong Revenue Growth of 47%. Conference call will be held today, Thursday, May 9 at 9:00 am ET Carmel, IN, May 9, 2024 /PRNewswire/ —Syra Health Corp. (NASDAQ: SYRA), (“Syra Health” or the “Company”) a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today its financial results for the first quarter ended March 31, 2024. Q1 2024 Financial Hig ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to ___________ Commission File Number: 001-41822 SYRA HEALTH CORP. (Exact Name of Registrant as Specified in its Charter) Delaware 85-4027995 (State or ...

Exhibit 99.1 Syra Health Announces Fourth-Quarter and Full-Year 2023 Financial Results. Projects 2024 Revenue Growth of 64% to 100%. Conference call will be held today, Monday, March 25 at 9:00am ET Carmel, IN, March 25, 2024 /PRNewswire/ —Syra Health Corp. (NASDAQ: SYRA), (“Syra Health” or the “Company”) a healthcare consulting company with a mission to improve healthcare by providing innovative services and technology solutions, today announced its financial results for the fourth quarter and fiscal year ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______ to______. Commission File Number 001-41822 SYRA HEALTH CORP. (Exact Name of Registrant as Specified in Its Charter) Delaware 85-4027995 (State or other jurisdiction of (I.R.S. ...

Syra Health Corp. (NASDAQ:SYRA) Q4 2023 Earnings Call Transcript March 25, 2024 9:00 AM ET Company Participants Ben Shamsian - IR Deepika Vuppalanchi - CEO Sandeep Allam - Executive Chairman and President Priya Prasad - CFO Operator Good morning, ladies and gentlemen, and welcome to Syra Health Fourth Quarter and Full Year 2023 Financial Results Conference Call. At this time, all lines are in a listen-only mode. [Operator Instructions] This call is being recorded on Monday, March 25, 2024. I would now like ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to ___________ Commission File Number: 001-41822 SYRA HEALTH CORP. (Exact Name of Registrant as Specified in its Charter) Delaware 85-4027995 (Stat ...